The biotech industry is one of Taiwan’s key industries that the Taiwanese government is actively promoting with the aim of strengthening international partnerships and growing export services. According to Biotechgate data, biotech companies account for 41% (263) of the total 640 life science companies in Taiwan.
As for most other countries, the pandemic boosted the domestic biotech industry of Taiwan in 2021, leading to a record high of USD 89 million in private equity investments. The market cooled off in 2022, reaching only half the amount of venture capital financing (USD 43 million). The largest Taiwan equity round in 2022 was secured by BRIM Biotechnology, Inc., which raised USD 20 million in a Series E round in December.
For more information, please read our report. Many thanks to our partner, Taiwan Bio Industry Organization, with whom we prepared this trend analysis.